Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials
Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.
Pfizer tested a new medicine called LITFULO that helped people with a skin condition where they lose color, and the results were good enough that they're now asking governments to approve it. This means the company is moving forward with a treatment that could help patients, which is something to notice when thinking about whether Pfizer is making progress.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.